Modulation of the neuronal nicotinic acetylcholine receptor-channel by the nootropic drug nefiracetam

Brain Research

Volumn 822, Issue 1-2, 1999, Pages 72-79

  Oyaizu, Miki ^a   Narahashi, Toshio ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acetylcholine receptor; G protein; Nefiracetam; Nootropic drug; PC12 cell; Protein kinase

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR; NEFIRACETAM; NOOTROPIC AGENT; PROTEIN G; PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CELL STRAIN; CHOLINERGIC SYSTEM; COGNITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; NEUROTRANSMISSION; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION;

ACETYLCHOLINE; ANIMALS; CARBAZOLES; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GTP-BINDING PROTEINS; INDOLES; MEMBRANE POTENTIALS; NAPHTHALENES; NEURONS; NOOTROPIC AGENTS; PATCH-CLAMP TECHNIQUES; PC12 CELLS; PERTUSSIS TOXIN; PROTEIN KINASE C; PYRROLES; PYRROLIDINONES; RATS; RECEPTORS, NICOTINIC; SIGNAL TRANSDUCTION; VIRULENCE FACTORS, BORDETELLA;

EID: 0033586289     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01077-X     Document Type: Article

References (51)

1. S.P. Arneric, M. Williams, Nicotinic agonists in Alzheimer's disease: does the molecular diversity of nicotine receptors offer the opportunity for developing CNS selective cholinergic channel activators?, in: G. Racagni, N. Brunello, S.Z. Langer (Eds.), Recent Advances in the Treatment of Neuro-degenerative Disorders and Cognitive Function, Vol. 7, Karger, Basel, 1994, pp. 58-70.
2. S.P. Arneric, J.P. Sullivan, C.A. Briggs, D. Donnelly-Roberts, D.J. Anderson, J.L. Raszkiewicz, M.L. Hughes, E.D. Cadman, P. Adams, D.S. Garvey, J.T. Wasicak, M. Williams, (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: 1. In vitro characterization, J. Pharmacol. Exp. Ther. 270 (1994) 310-318.
3. A. Copani, A.A. Genazzani, G. Aleppo, G. Casabona, P.L. Canonico, V. Scapagnini, F. Nicoletti, Nootropic drugs positively modulate α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid-sensitive glutamate receptors in neuronal cultures, J. Neurochem. 58 (1992) 1199-1204.
4. L.M. Colquhoun, J.W. Patrick, Pharmacology of neuronal nicotinic acetylcholine receptor subtypes, Adv. Pharmacol. 39 (1997) 191-220.
5. E.M. Fenwick, A. Marty, E. Neher, A patch-clamp study of bovine chromaffin cells and of their sensitivity to acetylcholine, J. Physiol. 331 (1982) 577-597.
6. K.F. Funk, J. Schmidt, Changes of dopamine metabolism by hypoxia and effect of nootropic drugs, Biomed. Biochem. Acta 11 (1984) 1301-1304.
7. J.-L. Galzi, F. Revah, A. Bessis, J.-P. Changeux, Functional architecture of the nicotinic acetylcholine receptor: from electric organ to brain, Annu. Rev. Pharmacol. 31 (1991) 37-72.
8. D.S. Garvey, J. Wasicak, M.W. Decker, J.D. Brioni, M.J. Buckley, J.P. Sullivan, G.M. Carrera, M.H. Holladay, S.P. Arneric, M. Williams, Novel isoxazoles which interact with brain cholinergic channel receptors that have intrinsic cognitive enhancing and anxiolytic activities, J. Med. Chem. 37 (1994) 1055-1059.
9. M.G. Giovannini, G. Spignoli, V. Carla, G. Pepeu, A decrease in brain catecholamines prevents oxiracetam antagonism of the effects of scopolamine on memory and brain acetylcholine, Pharmacol. Res. 24 (1991) 395-405.
10. A.H. Gouliaev, A. Senning, Piracetam and other structurally related nootropics, Brain Res. Rev. 19 (1994) 180-222.
11. A receptor-channel complex in dorsal root ganglion neurons, Neuropharmacology 35 (1996) 1251-1261.
12. C.K. Ifune, J.H. Steinbach, Modulation of acetylcholine-elicited currents in clonal rat phaeochromocytoma (PC12) cells by internal polyphosphates, J. Physiol. 463 (1993) 431-447.
13. J.S. Isaascon, R.A. Nicoll, Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus, Proc. Natl. Acad. Sci. U.S.A. 188 (1991) 10936-10940.
14. I. Ito, S. Tanabe, A. Kohda, H. Sugiyama, Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam, J. Physiol. 424 (1990) 533-543.
15. J. Itoh, T. Nabeshima, T. Kameyama, Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock, Psychopharmacology 101 (1990) 27-33.
16. T. Kameyama, T. Nabeshima, K. Tohyama, S. Ogawa, K. Murase, S. Ishihara, DM-9384, a pyrrolidone derivative, ameliorates basal forebrain lesion-induced amnesia and inhibits cycloheximide-induced decrease in the number of GABA and acetylcholine receptors, Adv. Behav. Biol. 38B (1990) 371-374.
17. A. Karlin, Structure of nicotine acetylcholine receptors, Curr. Opin. Neurobiol. 3 (1993) 299-309.
18. S. Kawajiri, T. Sakurai, H. Ojima, Effect of DM-9384, a new pyrrolidone derivative, on learning behavior and cerebral choline acetyltransferase activity in rats, Psychopharmacology 96 (1988) 32.02.24 (Suppl. Abstr.).
19. S. Kawajiri, K. Taniguchi, T. Sakurai, H. Kojima, T. Yamasaki, Effect of DM-9384 on extracellular acetylcholine in the rat frontal cortex measured with microdialysis, Eur. J. Pharmacol. 183 (1990) 928.
20. O.A. Krishtal, V.I. Pidoplichko, A receptor for protons in the nerve cell membrane, Neuroscience 5 (1980) 2325-2327.
21. J. Lindstrom, Neuronal nicotinic acetylcholine receptors, in: T. Narahashi (Ed.), Ion Channels, Vol. 4, Plenum, New York, 1996, pp. 377-450.
22. J. Lindstrom, Nicotinic acetylcholine receptors in health and disease, Mol. Neurobiol. 15 (1997) 193-222.
23. A receptor channels, Annu. Rev. Neurosci. 17 (1994) 569-602.
24. M. Magnani, O. Pozzi, R. Biagetti, S. Banfi, L. Dorigotti, Oxiracetam antagonizes the irruptive effects of scopolamine on memory in the radial maze, Psychopharmacology 106 (1992) 175-178.
25. M. Marchi, E. Besana, M. Raiteri, Oxiracetam increases the release of endogenous glutamate from depolarized rat hippocampal slices, Eur. J. Pharmacol. 185 (1990) 247-249.
26. D.S. McGehee, L.W. Role, Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons, Annu. Rev. Physiol. 57 (1995) 521-546.
27. T. Nabeshima, Ameliorating effects of nefiracetam (DM-9384) on brain dysfunction, Drugs of Today 30 (1994) 357-379.
28. A and muscarinic receptors induced by cycloheximide, J. Pharmacol. Exp. Ther. 257 (1991) 271-275.
29. K. Nagata, G.L. Aistrup, C.-S. Huang, W. Marszalec, J.-H. Song, J.Z. Yeh, T. Narahashi, Potent modulation of neuronal nicotinic acetylcholine receptor-channel by ethanol, Neurosci. Lett. 217 (1996) 189-193.
30. K. Nagata, C.-S. Huang, J.-H. Song, T. Narahashi, Lead modulation of the neuronal nicotinic acetylcholine receptor in PC12 cells, Brain Res. 754 (1997) 21-27.
31. T. Nishiazaki, T. Matsuoka, T. Nomura, K. Sumikawa, T. Shiotani, S. Watabe, M. Yoshii, Nefiracetam modulates acetylcholine receptor currents via two different signal transduction pathways, Mol. Pharmacol. 53 (1998) 1-5.
32. M. Ohino, T. Yamamoto, I. Kitajima, S. Ueki, WEB 1881 FU ameliorates impairment of working memory induced by scopolamine and cerebral ischemia in the three-panel runaway task, Jpn. J. Pharmacol. 54 (1990) 53-60.
33. G. Pepeu, G. Spignoli, Nootropic drugs and brain cholinergic mechanisms, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 13 (1989) 77-88, Suppl.
34. G. Pepeu, G. Spignoli, M.G. Giovannini, M. Magnani, The relationship between the behavioral effects of cognition-enhancing drugs and brain acetylcholine. Nootropic drugs and brain acetylcholine, Pharmacopsychiatry 22 (1989) 116-119, Suppl. 2.
35. L.W. Role, D.K. Berg, Nicotinic receptors in the development and modulation of CNS synapses, Neuron 16 (1996) 1077-1085.
36. T. Sakurai, H. Ojima, T. Yamasaki, H. Kojima, A. Akashi, Effects of N-(2, 6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide (DM-9384) on learning and memory in rats, Jpn. J. Pharmacol. 50 (1989) 47-53.
37. M. Sansone, C. Castellano, M. Battaglia, M. Ammassari-Teule, Oxiracetam prevents mecamylamine-induced impairment of active, but not passive, avoidance learning in mice, Pharmacol. Biochem. Behav. 36 (1990) 389-392.
38. M. Sarter, Taking stock of cognition enhancers, Trends Pharmacol. Sci. 12 (1991) 456-461.
39. M. Satoh, K. Ishihara, T. Iwama, H. Takagi, Aniracetam augments, and midazolam inhibits, the long-term potentiation in guinea-pig hippocampal slices, Neurosci. Lett. 68 (1986) 216-220.
40. A receptors, Trends Pharmacol. Sci. 16 (1995) 162-168.
41. G. Spignoli, G. Pepeu, Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine, Pharmacol. Biochem. Behav. 27 (1987) 491-495.
42. W. Stühmer, A.B. Parekh, Electrophysiological recordings from Xenopus oocytes, in: B.Sakmann, E. Neher (Eds.), Single-Channel Recording, Plenum, New York, 1995, pp. 341-356.
43. C.M. Tang, Q.Y. Shi, A. Katchman, G. Lynch, Modulation of the time course of fast EPSCs and glutamate channel kinetics by aniracetam, Science 254 (1991) 288-290.
44. K. Tohyama, T. Nabeshima, T. Kameyama, Effect of DM-9384, a pyrrolidone derivative, on benzodiazepine-induced amnesia, Psychopharmacology 96 (1988) 32.02.23 (Suppl. Abstr.).
45. K. Toide, Effects of aniracetam on one-trial passive avoidance tests and cholinergic neurons in discrete brain regions of rats, Arch. Int. Pharmacodyn. Ther. 298 (1989) 25-37.
46. R. Verloes, A.M. Scotto, J. Gobertand, E. Wuelfert, Effects of nootropic drugs in a scopolamine-induced amnesia model in mice, Psychopharmacology 95 (1988) 226-230.
47. S. Watabe, M. Yoshii, Ion channels and cognitive enhancers, Jpn. J. Neuropsychopharmacol. 15 (1993) 249-257.
48. S. Watanabe, H. Yamaguchi, S. Ashida, Effects of DM-9384 a new cognition-enhancing agent, on GABA release and choline uptake in rat cortex: Part I, Neurosci. Abstr. 15 (1989) 601.
49. S. Watabe, H. Yamaguchi, S. Ashida, DM-9384, a new cognition-enhancing agent, increases the turnover of components of the GABAergic system in the rat cerebral cortex, Eur. J. Pharmacol. 238 (1993) 303-309.
50. S. Wonnacott, Presynaptic nicotinic ACh receptors, Trends Neurosci. 20 (1997) 92-98.
51. M. Yoshii, S. Watabe, Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells, Brain Res. 642 (1994) 123-131.